---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-055981"
form_type: "8-K"
ticker: "BCYC"
cik: "0001761612"
company_name: "BICYCLE THERAPEUTICS PLC"
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:44:40.459601+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bicycle Therapeutics Q1 net loss narrows to $26.6M; cash $457M; Phase 2/3 trial initiated

## Summary
- Cash and equivalents $457.0M as of Mar 31, 2024, down from $526.4M at Dec 31, 2023.
- Net loss of $26.6M ($0.62 per share) vs $39.1M ($1.30) in Q1 2023; improvement helped by $8.2M retroactive UK R&D tax credits.
- R&D expenses rose to $34.9M from $32.2M YoY, driven by BT8009 clinical program costs.
- Initiated Phase 2/3 Duravelo-2 registrational trial for BT8009 in metastatic urothelial cancer; enrollment ongoing.
- Mike Hannay promoted to Chief Product and Supply Chain Officer; multiple clinical data readouts expected in 2H 2024.

## SEC filing metadata
- accession: 0001104659-24-055981
- form_type: 8-K
- ticker: BCYC
- cik: 0001761612
- company_name: BICYCLE THERAPEUTICS PLC
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761612/000110465924055981/0001104659-24-055981-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761612/000110465924055981/tm2413108d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-055981
- JSON: https://secwatch.observer/filing/0001104659-24-055981.json
- Plain text: https://secwatch.observer/filing/0001104659-24-055981.txt

## Key facts
- Earnings Releases
  BICYCLE THERAPEUTICS PLC reported first quarter ended March 31, 2024 results: net income Net loss was $26.6 million, EPS $(0.62) basic and diluted net loss per share.
  - Period: first quarter ended March 31, 2024
  - Net income: Net loss was $26.6 million
  - EPS: $(0.62) basic and diluted net loss per share
  - Result: reported results
  source text: Net loss was $26.6 million, or $(0.62) basic and diluted net loss per share, for the three months ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761612/000110465924055981/0001104659-24-055981-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.